Quick Read
-
500 shares each of PFE and JNJ generate $3,540 in annual passive income on a $127,000 investment at a blended 2.79% yield.
-
JNJ’s 64th consecutive dividend increase to $1.34 quarterly is backed by a AAA-rated balance sheet and $19.7 billion in free cash flow.
-
Pfizer’s 6.8% yield reflects stock compression, with CEO Albert Bourla prioritizing the dividend over buybacks while Padcev jumped 39% in Q1 2026.
-
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Johnson & Johnson didn’t make the cut. Grab the names FREE today.
Passive income is the closest thing investors have to financial gravity. It pulls in money whether you are at your desk, on a beach, or asleep, and it lands in your account no matter what the broader market did that week. Earned income depends on showing up. Dividend income depends on a board of directors keeping a promise it has often kept for decades.
Healthcare megacaps have quietly become the bedrock of that promise. Two of the most widely held names in the sector, Pfizer (NYSE:PFE) and Johnson & Johnson (NYSE:JNJ), write checks four times a year to shareholders regardless of what biotech sentiment, election cycles, or Treasury yields are doing. Compared with rental property or private credit, a 500-share position can be liquidated in seconds and rebalanced without a closing attorney.
We screened our 24/7 Wall St. dividend equity research database, looking for stocks that pay massive dividends, and we found a collection of companies that, combined, can generate over $3,500 a year in passive annual income if you invest just 500 shares in each stock at the time of this writing.
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Johnson & Johnson didn’t make the cut. Grab the names FREE today.
Johnson & Johnson
Johnson & Johnson is a diversified healthcare giant operating two reporting segments: Innovative Medicine and MedTech. The pharma side delivered $15.426 billion in Q1 2026 revenue, up 11.2% year over year, fueled by DARZALEX, TREMFYA, and CARVYKTI. The MedTech business added $8.636 billion, up 7.7%, with electrophysiology and Abiomed driving cardiovascular growth.
The dividend is built on reliability rather than headline yield. JNJ just declared its 64th consecutive annual dividend increase, raising the quarterly payout 3.1% to $1.34, payable June 9, 2026. That Dividend King status is structural: a AAA-rated balance sheet, 21.8% profit margins, and $19.7 billion in free cash flow last year back every quarterly check.
